申请人:Rigel Pharmaceuticals, Inc.
公开号:US10421752B2
公开(公告)日:2019-09-24
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
本发明包括具有式 I-V 的化合物,以及使用这些化合物治疗 JAK 通路调节或 JAK 激酶(尤其是 JAK3)抑制可能具有治疗作用的疾病的组合物和方法。